In recent years, synthetic lethality has been recognized as a solid paradigm for anticancer
therapies. The discovery of a growing number of synthetic lethal targets has led to a …

Tumor cells can result from gene mutations and over-expression. Synthetic lethality (SL)
offers a desirable setting where cancer cells bearing one mutated gene of an SL gene pair …

Synthetic lethality (SL) is a gold mine of anticancer drug targets, exposing cancer-specific
dependencies of cellular survival. To complement resource-intensive experimental …

Tissue-specific differences in the expression of paralog genes, which are not essential in
most cell types due to the buffering effect of the partner pair, can make for highly selective …

Synthetic lethal (SL) genetic interactions have been regarded as a promising focus for
investigating potential targeted therapeutics to tackle cancer. However, the costly investment …

Synthetic lethality (SL) has shown great promise for the discovery of novel targets in cancer.
CRISPR double-knockout (CDKO) technologies can only screen several hundred genes …

Synthetic lethality is a phenomenon wherein the simultaneous deficiency of two or more
genes results in cell death, while the deficiency of any individual gene does not lead to cell …

In biological network analysis, identifying key molecules plays a decisive role in the
development of potential diagnostic and therapeutic candidates. Among various approaches …

Background Prostate cancer stands as the second most common malignancy among men,
notorious for its intricate heterogeneity, especially evident in metastatic disease. This …

Cancer is a complex disease driven by multiple genetic changes, including mutations in
oncogenes, tumor suppressor genes, DNA repair genes, and genes involved in cancer …